Apricus Biosciences Inc (APRI) 2.23 $APRI
Apricus' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 9 mins ago
Apricus Biosciences, Inc.'s (APRI) loss in narrows in the first quarter of 2014.
Apricus Biosciences Provides Corporate Update and First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 3:07PM CDT
Takeda Begins Sampling Effort of Vitaros in the United Kingdom
Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa(TM) for Secondary Raynaud's Phenomenon
GlobeNewswire - Mon May 12, 3:07PM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application allowing the Company to initiate clinical testing of RayVa, Apricus' product candidate for the treatment of Raynaud's phenomenon. The Company expects to commence a Phase 2a clinical trial and begin enrollment in the second half of 2014. RayVa combines alprostadil, a vasodilator, with Apricus' proprietary permeation enhancer DDAIP.HCl, and is applied as an on-demand topical cream to affected extremities. In a nonclinical model, the Company demonstrated topical administration of alprostadil cream to cold-challenge statistically improved blood flow by 30 minutes relative to placebo, as measured by Laser Doppler. The improvement in blood flow was maintained out to 90 minutes post-challenge.
Global Erectile Dysfunction Therapeutics Pipeline Review 2014 - Analysis of 16 Companies
M2 - Tue Apr 29, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkfwf9/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Sanofi - Suda Ltd - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - IntelGenx Corp. - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - Yuhan Corporation - Futura Medical plc - Fabre-Kramer Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - Aprogen, Inc. - Furiex Pharmaceuticals, Inc. - NanoForm Therapeutics Ltd. - Sagene Pharmaceuticals, Inc. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/tkfwf9/erectile
Apricus Biosciences Announces Corporate Update and First Quarter 2014 Financial Results Conference Call
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company's first quarter financial results will be released after market close on Monday, May 12, 2014. Company management will host a conference call on Monday, May 12, 2014, at 5:00 p.m. ET to discuss these results and other recent corporate highlights.
Apricus Biosciences wins national phase approval for Vitaros in Spain for the ED market
M2 - Fri Apr 25, 4:37AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) revealed on Thursday the receipt of the national phase approval for its novel topical on-demand treatment for erectile dysfunction (ED) in Spain, Vitaros.
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Spain
GlobeNewswire - Thu Apr 24, 7:00AM CDT
Vitaros National Phase Approval Process in Europe Completed
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Apricus Biosciences' partner to be the first to launch Vitaros for treating erectile dysfunction in Europe
M2 - Thu Apr 17, 5:23AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Wednesday the first shipment of its novel topical on-demand treatment for erectile dysfunction (ED) Vitaros in the UK.
Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of Vitaros(R)
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Takeda UK to be the First to Launch Vitaros in Europe
Apricus Biosciences and Its European Partners to Sponsor Symposium on Vitaros(R) at the European Association of Urology (EAU) Congress, Stockholm
GlobeNewswire - Mon Apr 07, 7:01AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company, along with its European commercial partners, is sponsoring a symposium - "A New Paradigm in the Treatment of ED - The Topical Option" - during the European Association of Urology (EAU) Congress. Vitaros is Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"
, approved in Canada and nine countries in Europe. The symposium will take place in the Stockholmsmassan Exhibition & Convention Center, Room K2, on Friday, April 11 at 4:15 pm DST.
Apricus Biosciences receives national phase approval for Vitaros in Luxembourg & on track for its planned market launch in 2014
M2 - Fri Apr 04, 7:31AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) reported on Thursday the receipt of national phase approval for its novel topical on-demand treatment for erectile dysfunction (ED), Vitaros, in Europe from the Ministry of Health of Luxembourg.
Apricus' Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:54PM CDT
Apricus posted a loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents per share and far better than the year-ago loss of 25 cents per share.
Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton as Vice President, Business Development
GlobeNewswire - Thu Mar 20, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the appointment of Neil C. Morton as Vice President of Business Development. Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. He will report to Richard Pascoe, Apricus' Chief Executive Officer, and his appointment is effective immediately. Edward Cox, who previously served in this position, will transition to the newly created role of Vice President of Commercial Development where he will primarily focus on supporting the launch of Vitaros in Europe and Canada.
Apricus Biosciences Provides Corporate Update and 2013 Year-End Financial Results
GlobeNewswire - Mon Mar 17, 3:03PM CDT
- Vitaros Remains on Track to Launch in Europe and Canada in 2014 -
Apricus Biosciences hires Dr Wendell Wierenga to board
M2 - Tue Mar 11, 6:09AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Monday the addition of Wendell Wierenga PhD, to its board of directors with immediate effect.
Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to the Company's Board of Directors. Dr. Wierenga brings decades of experience heading research and development programs that led to the marketing approval of over 15 medicines and has participated in the filing of over 70 Investigational New Drug (IND) disclosures. His appointment is effective immediately.
Apricus Biosciences Announces Corporate Update and 2013 Year-End Financial Results Conference Call
GlobeNewswire - Mon Mar 10, 3:05AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) announced today that it will host a conference call on Monday, March 17, 2014, at 5:00 p.m. ET to discuss recent corporate highlights and its fourth quarter and year-end 2013 financial results.
Apricus Biosciences to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:31AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced that Richard Pascoe, Chief Executive Officer, will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. Pacific Time. The conference will be held at the Ritz-Carlton in Dana Point, CA.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
Apricus' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 9 mins ago
Apricus Biosciences, Inc.'s (APRI) loss in narrows in the first quarter of 2014.
Apricus Biosciences Provides Corporate Update and First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 3:07PM CDT
Takeda Begins Sampling Effort of Vitaros in the United Kingdom
Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa(TM) for Secondary Raynaud's Phenomenon
GlobeNewswire - Mon May 12, 3:07PM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application allowing the Company to initiate clinical testing of RayVa, Apricus' product candidate for the treatment of Raynaud's phenomenon. The Company expects to commence a Phase 2a clinical trial and begin enrollment in the second half of 2014. RayVa combines alprostadil, a vasodilator, with Apricus' proprietary permeation enhancer DDAIP.HCl, and is applied as an on-demand topical cream to affected extremities. In a nonclinical model, the Company demonstrated topical administration of alprostadil cream to cold-challenge statistically improved blood flow by 30 minutes relative to placebo, as measured by Laser Doppler. The improvement in blood flow was maintained out to 90 minutes post-challenge.
Global Erectile Dysfunction Therapeutics Pipeline Review 2014 - Analysis of 16 Companies
M2 - Tue Apr 29, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkfwf9/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Sanofi - Suda Ltd - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical Corp. - IntelGenx Corp. - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - Yuhan Corporation - Futura Medical plc - Fabre-Kramer Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - Aprogen, Inc. - Furiex Pharmaceuticals, Inc. - NanoForm Therapeutics Ltd. - Sagene Pharmaceuticals, Inc. - LondonPharma Ltd For more information visit http://www.researchandmarkets.com/research/tkfwf9/erectile
Apricus Biosciences Announces Corporate Update and First Quarter 2014 Financial Results Conference Call
GlobeNewswire - Mon Apr 28, 7:01AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company's first quarter financial results will be released after market close on Monday, May 12, 2014. Company management will host a conference call on Monday, May 12, 2014, at 5:00 p.m. ET to discuss these results and other recent corporate highlights.
Apricus Biosciences wins national phase approval for Vitaros in Spain for the ED market
M2 - Fri Apr 25, 4:37AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) revealed on Thursday the receipt of the national phase approval for its novel topical on-demand treatment for erectile dysfunction (ED) in Spain, Vitaros.
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Spain
GlobeNewswire - Thu Apr 24, 7:00AM CDT
Vitaros National Phase Approval Process in Europe Completed
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Apricus Biosciences' partner to be the first to launch Vitaros for treating erectile dysfunction in Europe
M2 - Thu Apr 17, 5:23AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Wednesday the first shipment of its novel topical on-demand treatment for erectile dysfunction (ED) Vitaros in the UK.
Apricus Biosciences' Partner in the United Kingdom Accepts First Shipment of Vitaros(R)
GlobeNewswire - Wed Apr 16, 7:30AM CDT
Takeda UK to be the First to Launch Vitaros in Europe
Apricus Biosciences and Its European Partners to Sponsor Symposium on Vitaros(R) at the European Association of Urology (EAU) Congress, Stockholm
GlobeNewswire - Mon Apr 07, 7:01AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company, along with its European commercial partners, is sponsoring a symposium - "A New Paradigm in the Treatment of ED - The Topical Option" - during the European Association of Urology (EAU) Congress. Vitaros is Apricus' novel topical on-demand treatment for erectile dysfunction ("ED"
, approved in Canada and nine countries in Europe. The symposium will take place in the Stockholmsmassan Exhibition & Convention Center, Room K2, on Friday, April 11 at 4:15 pm DST. Apricus Biosciences receives national phase approval for Vitaros in Luxembourg & on track for its planned market launch in 2014
M2 - Fri Apr 04, 7:31AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) reported on Thursday the receipt of national phase approval for its novel topical on-demand treatment for erectile dysfunction (ED), Vitaros, in Europe from the Ministry of Health of Luxembourg.
Apricus' Loss Narrows in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:54PM CDT
Apricus posted a loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 6 cents per share and far better than the year-ago loss of 25 cents per share.
Apricus Biosciences Expands Senior Management Team, Appointing Neil C. Morton as Vice President, Business Development
GlobeNewswire - Thu Mar 20, 7:00AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced the appointment of Neil C. Morton as Vice President of Business Development. Mr. Morton brings to Apricus a successful track record in business development in specialty pharmaceuticals, most recently serving as the Executive Director of Business Development at Auxilium Pharmaceuticals Inc., where he successfully led their efforts to build a pipeline of men's health products to include in-licensing of Stendra(TM) from Vivus, Inc. and the acquisition of Actient Pharmaceuticals. He will report to Richard Pascoe, Apricus' Chief Executive Officer, and his appointment is effective immediately. Edward Cox, who previously served in this position, will transition to the newly created role of Vice President of Commercial Development where he will primarily focus on supporting the launch of Vitaros in Europe and Canada.
Apricus Biosciences Provides Corporate Update and 2013 Year-End Financial Results
GlobeNewswire - Mon Mar 17, 3:03PM CDT
- Vitaros Remains on Track to Launch in Europe and Canada in 2014 -
Apricus Biosciences hires Dr Wendell Wierenga to board
M2 - Tue Mar 11, 6:09AM CDT
Pharmaceutical company Apricus Biosciences (NasdaqCM:APRI) disclosed on Monday the addition of Wendell Wierenga PhD, to its board of directors with immediate effect.
Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board of Directors
GlobeNewswire - Mon Mar 10, 7:30AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to the Company's Board of Directors. Dr. Wierenga brings decades of experience heading research and development programs that led to the marketing approval of over 15 medicines and has participated in the filing of over 70 Investigational New Drug (IND) disclosures. His appointment is effective immediately.
Apricus Biosciences Announces Corporate Update and 2013 Year-End Financial Results Conference Call
GlobeNewswire - Mon Mar 10, 3:05AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) announced today that it will host a conference call on Monday, March 17, 2014, at 5:00 p.m. ET to discuss recent corporate highlights and its fourth quarter and year-end 2013 financial results.
Apricus Biosciences to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:31AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), today announced that Richard Pascoe, Chief Executive Officer, will present at the 26 Annual ROTH Conference on Tuesday, March 11, 2014, at 3:00 p.m. Pacific Time. The conference will be held at the Ritz-Carlton in Dana Point, CA.
Encana Delivers on Its Targets in a Year of Change, Well Positioned for 2014
Marketwire Canada - Thu Feb 13, 5:00AM CST
Encana Corporation (TSX:ECA)(NYSE:ECA) concluded 2013 by meeting or exceeding guidance on all of its key operating and financial metrics during a year in which it announced a new President & CEO and launched a bold change in its strategy. Solid results have already been achieved on primary themes of the strategy announced by the company in the fourth quarter, including significant year-over-year increases in liquids production and ending the year with strong cash flow and a strong balance sheet.
